Participate in Enrolling Studies
Participating in research is one of the most meaningful ways to help advance the future of health care. Many studies involve individuals who are experiencing memory concerns or have risk factors for dementia, while others welcome healthy volunteers with no symptoms. If you are interested in learning more, talk with your physician about whether you may be eligible for one of the studies listed below. Your health care team can help determine if participation is appropriate based on your health history, risk factors, and personal circumstances.
Many of today's treatments are available because individuals chose to take part in research studies. If you have the opportunity to participate in a clinical study or trial, we hope you will consider it.
NT-ADRC Study
The NT-ADRC study is looking at how high blood pressure and other heart and metabolic health conditions may affect the brain and increase the risk of Alzheimer's disease and related dementias. Researchers use health information, brain scans, blood and other lab tests, and long-term follow-up to learn how these conditions may contribute to memory loss over time. The goal is to find better ways to detect Alzheimer's disease early, identify who may be at higher risk, and support the development of new treatments and prevention strategies.
ADNI 4 – The Alzheimer's Disease Neuroimaging Initiative
ADNI 4 is a nationwide study that follows adults ages 55 to 90 over five years to better understand how Alzheimer's disease develops. Participants undergo brain imaging, blood tests, and other assessments that help researchers track changes in the brain before symptoms become severe. Information from this study will help improve future Alzheimer's research, clinical trials, and efforts to prevent or delay dementia.
Local PI: Trung Nguyen, M.D. | Learn about ADNI 4
IPAT – Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults
The IPAT study is examining whether more intensive treatment of high blood pressure can help protect the brain from changes linked to Alzheimer's disease. The study includes older adults who may be at higher risk for dementia because of high blood pressure, a family history of dementia, or concerns about their memory. Participants receive advanced brain scans that allow researchers to measure proteins associated with Alzheimer's disease and better understand the relationship between blood pressure and brain health.
Local PI: Rong Zhang, Ph.D. | Learn about IPAT
TRC-DS – Trial Ready Cohort Down Syndrome
People with Down syndrome are at a much higher risk of developing Alzheimer's disease as they age. The TRC-DS study follows adults with Down syndrome ages 25 to 55 to better understand changes related to Alzheimer's disease and help prepare for future treatment studies. This international research effort aims to improve access to Alzheimer's research and support the development of therapies specifically for people with Down syndrome.
Local PI: Brendan Kelley, M.D. | Learn about TRC-DS
Multi-parametric MR imaging of Alzheimer's disease
This study is evaluating advanced MRI techniques that may help detect changes in the brain related to Alzheimer's disease earlier and more accurately than standard MRI scans. Researchers hope these new imaging methods will improve the ability to identify Alzheimer's-related changes, monitor disease progression, and understand who may be more likely to benefit from or experience side effects from newer Alzheimer's treatments.
Upcoming
RESIST-AD
This study aims to identify new, rare protective mutations that protect the brain from Alzheimer's disease. This approach is fundamentally distinct from the typical paradigm where risk factors are identified and treatments are employed to try to block or reduce them. Here, genetic changes that have already demonstrated safety and efficacy in humans by conferring resistance to AD offer a unique and potentially transformative path to safe, mechanism-driven therapies.
Local PI: Brendan Kelley, M.D. & Laurent Calvier, Ph.D.